Trials / Completed
CompletedNCT04453501
Anti Infective Agents Impact in COVID-19 Pneumonia
Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 132 (actual)
- Sponsor
- Centre d'Investigation Clinique et Technologique 805 · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone. Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | favorable outcome | Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death) |
Timeline
- Start date
- 2020-03-02
- Primary completion
- 2020-04-25
- Completion
- 2020-04-25
- First posted
- 2020-07-01
- Last updated
- 2020-07-01
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04453501. Inclusion in this directory is not an endorsement.